NCT07131059View on ClinicalTrials.gov

MRD-positive AML Clinical Study

NARecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

May 11, 2024

Primary Completion Date

May 10, 2026

Study Completion Date

April 30, 2028

Conditions

AML, Adult

Interventions

DRUG

Ivosidenib

500mg d1-28

DRUG

Gilteritinib

120mg d1-28

DRUG

Venetoclax

400mg d1-21 ; 400mg d1-7;400mg d1-28; 600mg d1-21

DRUG

Avapritinib

200mg d1-28.

DRUG

Daunorubicin

45mg/m2/d d1-2;

DRUG

Cytarabine

100mg/m2/d d1-5

DRUG

Idarubicin

10mg/m2/d d1-2

DRUG

MTZ

8mg/m2/d d1-2

DRUG

HHT

2mg/m2/d d1-5

DRUG

Azacitidine

75mgd/m2 d1-7.

Trial Locations (1)

300020

RECRUITING

Blood Diseases Hospital, Tianjin

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER